Development
Cullinan Therapeutics, Inc.
CGEM
$7.85
-$0.235-2.91%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 39.25% | -21.63% | 44.42% | -116.42% | -7.97% |
| Total Depreciation and Amortization | -3.75% | -1.23% | 12.50% | 22.03% | 555.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.57% | -10.94% | 1.09% | -15.38% | 26.05% |
| Change in Net Operating Assets | 1,928.73% | 96.11% | -493.90% | 123.55% | 85.65% |
| Cash from Operations | 46.89% | -10.11% | 39.20% | -104.13% | 54.04% |
| Capital Expenditure | -- | 100.00% | 69.18% | 81.97% | -251.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | 219.81% | -453.30% | -20.75% | 155.15% | 55.65% |
| Cash from Investing | 219.81% | -454.73% | -20.24% | 153.07% | 50.65% |
| Total Debt Issued | -- | -- | -100.00% | 942.86% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 121.43% | -99.71% | -- | -- | -86.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | 99.89% | -- |
| Cash from Financing | 121.43% | -99.71% | 2,057.74% | 105.44% | -2,409.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 143.63% | -490.68% | 157.92% | 60.67% | 22.00% |